考虑不依从的贝叶斯II期临床试验设计
针对早期临床试验中常见的不依从问题,该研究提出一种贝叶斯序贯监测方法,采用主分层框架和贝叶斯加性回归树估计依从者平均因果效应(CACE),并据此自适应决定是否提前终止。模拟研究证实该设计在不依从情形下表现优异。
要点
- 不依从可导致意向性治疗效应估计偏倚和错误结论。
- 采用主分层框架与贝叶斯加性回归树估计CACE。
- 基于累积数据估计的CACE自适应决定是否提前终止。
核心结论
- 提出的贝叶斯设计在不依从存在时通过估计CACE进行序贯监测,模拟研究证实其性能优异。
研究设计与样本
- 提出贝叶斯方法用于II期随机临床试验的序贯监测,考虑不依从信息。
- 采用主分层框架,使用贝叶斯加性回归树选择基线协变量并估计疗效与毒性结局的CACE。
主要发现
- 模拟研究证实所提设计在不依从情形下表现优异。
临床怎么用
- 在II期随机临床试验中考虑不依从信息,基于CACE自适应决定是否提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Noncompliance issue is common in early phase clinical trials; and may lead to biased estimation of the intent-to-treat effect and incorrect conclusions for the clinical trial. In this work, we propose a Bayesian approach for sequentially monitoring the phase II randomized clinical trials that takes account for the noncompliance information. We adopt the principal stratification framework and propose to use Bayesian additive regression trees for selecting useful baseline covariates and estimating the complier average causal effect (CACE) for both efficacy and toxicity outcomes. The decision of early termination or not is then made adaptively based on the estimated CACE from the accumulated data. Simulation studies have confirmed the excellent performance of the proposed design in the presence of noncompliance.
引用
- Ren T, Shen W, Zhang L, et al. Bayesian phase II clinical trial design with noncompliance. Stat Med. 2021. PMID: 34050539. doi:10.1002/sim.9041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。